Atrium's ATR 1072 Doses First in Genetic Cardiomyopathy Trial
Atrium's Leap in Genetic Cardiomyopathy You know you're living in fascinating times when a company like Atrium Therapeutics rolls the dice on RNA therapeutics, aiming to tackle heart diseases at the genetic level. And that's precisely what they did! They just dosed the first patient in the Phase 1/2 Corventis trial with their drug ATR 1072, setting sail on uncharted...
Continue Reading